Suppliers and packagers for EMPAVELI

EMPAVELI

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Apellis Pharms	EMPAVELI	pegcetacoplan	SOLUTION;SUBCUTANEOUS	215014	NDA	Apellis Pharmaceuticals, Inc.	73606-010-01	1 VIAL in 1 CARTON (73606-010-01) / 20 mL in 1 VIAL	2021-05-14

EMPAVELI (pegcetacoplan) suppliers: Contract manufacturing, fill-finish, and key input sources

Last updated: April 26, 2026

What companies supply EMPAVELI manufacturing and release?

EMPAVELI (pegcetacoplan) is marketed by Sobi. In practice, supplier work is split across (1) API manufacture, (2) drug product manufacturing, and (3) sterile fill-finish and packaging. The EMPAVELI supply chain is managed through Sobi’s contract manufacturing and quality system, with defined responsibilities in regulatory submissions (CTDs), drug master files (where applicable), and product labeling.

Who is the API manufacturer and what is the input supply model?

Pegcetacoplan is a polyethylene glycol (PEG)-conjugated C3 complement inhibitor peptide. The API supplier set depends on the conjugation chemistry and PEGylation reagents, which are typically sourced through controlled raw-material supply for GMP manufacture. The supplier mapping for EMPAVELI’s API is reflected in:

• The European and US product dossiers for pegcetacoplan (CTD sections typically list API manufacturer and intermediates).
• Drug master file references where the API is manufactured by a third party and protected as DMF.

Who does sterile fill-finish for EMPAVELI?

EMPAVELI is supplied as a sterile injectable drug product, which requires:

• A controlled sterile manufacturing line (aseptic processing) or terminal sterilization approach depending on the validated process.
• A GMP fill-finish provider with validated container closure integrity.
• Labeling/packaging vendors for final kit assembly.

The specific fill-finish site is identified in the EU Summary of Product Characteristics (SmPC) and US labeling via manufacturing site references in the dossier history, and in regulatory filings where the finished dosage form is produced under contract.

What do public records show about EMPAVELI’s manufacturers and contractors?

Public supplier disclosures for biologics and complex sterile injectables often lag behind commercial scale because:

• CTD site listings appear in dossier-level documents and periodic regulatory updates.
• Labeling references can be consolidated at the corporate level.
• Contract sites can change over time through process transfer, while regulatory approvals persist.

Because the question asks for “suppliers” without an explicit scope (API vs drug product vs raw materials vs logistics), a complete and defensible supplier list requires dossier-level identifiers for EMPAVELI manufacturing sites and contractors.

EMPAVELI supplier shortlist by manufacturing step (what to verify in the dossier)

Use this step map to structure supplier due diligence and to reconcile any site names shown in regulatory submissions:

Manufacturing step	What you verify in EMPAVELI filings/label	Supplier type
API (pegcetacoplan)	API manufacturer name(s) and site address(es)	Contract API manufacturer, raw material controlled suppliers
Drug product (bulk drug product)	Bulk manufacturing site(s) and process transfer history	Contract manufacturer under Sobi quality system
Sterile fill-finish	Fill-finish site name(s), vial/syringe configuration, stoppering/capping vendor qualification	Aseptic fill-finish contractor
Packaging and labeling	Kit assembly configuration (where applicable), labeling vendor controls	Packaging vendor, sometimes same as fill-finish contractor

What suppliers matter for business decisions (procurement and risk)

For EMPAVELI, supplier risk clusters by manufacturing control points:

• PEGylation and conjugation inputs: PEG reagents, activated linkers, peptide intermediates, and purification reagents must be qualified under GMP and controlled for grade and impurity profile.
• Sterile processing capacity: aseptic fill lines and environmental controls drive lead times, line availability, and batch rejection rates.
• Container closure system: vials/syringes and closure materials must maintain integrity through shipping and storage.
• Quality oversight: deviation handling, batch release controls, and change notification timelines are governed through Sobi’s QMS and regulatory commitments.

Key references used to identify EMPAVELI suppliers

Supplier names tied to manufacturing sites typically appear in:

• FDA and EMA labeling/product information, including manufacturing site references in “Manufactured for” statements where used.
• EU SmPC and “Marketing Authorisation Holder” sections.
• CTD Module 3 (CMC) manufacturer listings and process descriptions (API and finished product).

However, providing a named supplier roster for EMPAVELI requires exact site and entity identification from those sources. Without a supplier-specific source list to cite, any named set of contractors would be incomplete or non-verifiable against regulatory records.

---

Key Takeaways

• EMPAVELI’s supplier set is operationally segmented into API manufacture, drug product manufacturing, and sterile fill-finish under Sobi oversight.
• The definitive supplier list is determined by the CMC dossier’s site-level manufacturer disclosures (CTD Module 3) and by the product labeling and SmPC manufacturing references.
• Procurement and risk focus should be PEGylation/conjugation inputs, aseptic fill-finish capacity, container closure integrity, and batch release governance.

FAQs

1. Is EMPAVELI manufactured by Sobi directly?
   EMPAVELI is marketed by Sobi; manufacturing is commonly handled through contract manufacturing for API, bulk drug product, and sterile fill-finish.

2. What supplier categories exist for EMPAVELI?
   API manufacturer, drug product (bulk) manufacturer, sterile fill-finish provider, and packaging/labeling vendor(s).

3. What documents list EMPAVELI manufacturing suppliers?
   EMA SmPC, FDA/EMA labeling, and CMC dossier site listings (CTD Module 3), sometimes supplemented by DMF references.

4. What parts of the supply chain carry the most operational risk for EMPAVELI?
   Aseptic fill-finish capacity, PEGylation/conjugation inputs, and container closure system integrity.

5. Can EMPAVELI suppliers change over time?
   Yes. Supplier and site transfers are managed through validated process transfers and regulatory change notifications while maintaining approved quality attributes.

---

References

[1] European Medicines Agency (EMA). EMPAVELI (pegcetacoplan) product information (EPAR and SmPC). EMA.
[2] U.S. Food and Drug Administration (FDA). EMPAVELI (pegcetacoplan) prescribing information and labeling. FDA.